Related Experiment Videos
Vasoactive peptides, their receptors and drug development
1Center for Cardiovascular Research/Institute of Pharmacology and Toxicology, Campus Charité Mitte, Charité- Universitätsmedizin Berlin, Hessische Strasse 3-4, D-10115 Berlin, Germany. heike.kusserow@charite.de
Basic & Clinical Pharmacology & Toxicology
|January 17, 2004
Summary
This review discusses potent vasoconstrictors like angiotensin II and endothelin, their receptors, and new drugs targeting these pathways. It also covers enzyme inhibitors for managing vasoconstrictor actions.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
Background:
- Vasoactive peptides, such as angiotensin II and endothelin, are potent vasoconstrictors crucial in physiological and pathological states.
- These peptides exert effects through specific receptors, predominantly seven transmembrane G-protein coupled receptors.
Purpose of the Study:
- To review the properties and distribution of angiotensin II and endothelin.
- To focus on their receptors and novel antagonist drugs.
- To present indirectly acting drugs, including enzyme inhibitors.
Main Methods:
- Literature review of vasoactive peptides, their receptors, and associated drug development.
- Analysis of therapeutic strategies targeting vasoconstrictor pathways.
Main Results:
- Angiotensin II and endothelin are key vasoconstrictors acting via G-protein coupled receptors.
- Receptor antagonists and enzyme inhibitors (ACE inhibitors, ECE inhibitors) represent therapeutic strategies.
Conclusions:
- Targeting angiotensin II and endothelin pathways offers therapeutic potential for conditions involving vasoconstriction.
- Development of receptor antagonists and enzyme inhibitors provides valuable tools for managing vasoconstrictor actions.